INmune Bio (NASDAQ: INMB) announced the successful completion of its Phase I/II CaRe PC trial for INKmune™ in metastatic castration-resistant prostate cancer (mCRPC). The trial met both primary and secondary endpoints, with the treatment demonstrating excellent safety across all three dose levels.
Key findings include successful NK cell activation in over 50% of patients with advanced disease, with some patients showing tumor size reduction or complete disappearance. Following these positive results, the company plans to advance to a randomized Phase 2b trial focusing on patients with less severe disease to better evaluate the drug's clinical benefits.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.